Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 10/20 | 0.40 |
| ▸ | ATP4A | P20648 | 2/20 | 0.38 |
| ▸ | ATP4B | P51164 | 2/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4061237 | 1.00 | PPARG (0.45) | PPARGFFAR1PPARDPPARAATP4A | |
| SCHEMBL7028371 | 1.00 | PPARG (0.45) | PPARGFFAR1PPARDPPARAATP4A | |
| SCHEMBL6584128 | 0.86 | PPARG (0.62) | PPARGPPARAF2RL3 | |
| SCHEMBL8794428 | 0.85 | PPARG (0.41) | PPARGFFAR1PPARDPPARAATP4A | |
| SCHEMBL8794339 | 0.84 | FFAR1 (0.60) | PPARGFFAR1PPARDPPARA | |
| SCHEMBL7024314 | 0.82 | FFAR1 (0.41) | PPARGFFAR1PPARDPPARAATP4A | |
| SCHEMBL7162936 | 0.81 | FFAR1 (0.59) | PPARGFFAR1PPARDPPARA | |
| SCHEMBL7164834 | 0.80 | FFAR1 (0.58) | PPARGFFAR1PPARDPPARA | |
| SCHEMBL7025967 | 0.79 | FFAR1 (0.45) | PPARGFFAR1PPARDPPARAATP4A | |
| SCHEMBL8795234 | 0.78 | FFAR1 (0.62) | PPARGFFAR1PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134884-A1 | Neovascularization inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-07-17 | — | — | US | disclosed |
| EP-1277730-A1 | NEOVASCULARIZATION INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-01-22 | — | — | EP | disclosed |
| JP-2001213880-A | OPTICALLY ACTIVE OXAZOLIDINEDIONE COMPOUND | TAKEDA CHEM IND LTD | 2001-08-07 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134884-A1 | Neovascularization inhibitors | VEGFA, FLT1, FLT4 | PPARG 1641/4885FFAR1 3421/4885PPARD 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.